Company Overview
KORU Medical Systems, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops, manufactures, and commercializes subcutaneous infusion solutions. The company's primary business involves providing infusion systems designed to deliver therapies to patients suffering from chronic illnesses, with a significant focus on the subcutaneous drug delivery market across the United States and internationally. The firm employs a workforce of 73 individuals to support its operations in developing and commercializing these specialized medical technologies. Currently, KORU Medical Systems holds a market capitalization of $204.49M and generates annual revenue of $41.13M based on trailing twelve-month data. These valuation and revenue figures indicate that the company is a small-cap entity operating with a relatively modest revenue base compared to larger established medical device manufacturers, suggesting a position that relies heavily on growth potential and niche market penetration rather than established market dominance or massive scale.
Financial Health
The company reported a trailing twelve-month revenue of $41.13M, yet it posted a net income of $-2,637,926, revealing a significant gap where operating expenses and cost structures have exceeded gross profits. This negative net income is further reflected in an EBITDA figure of $-2,279,840, indicating that the company is currently burning cash through its core operations before accounting for interest and taxes. Despite the net loss, the business generated positive free cash flow of $385,832, which suggests that the company maintains a degree of financial flexibility and operational efficiency that allows it to generate cash from its activities despite accounting losses. The gross margin stands at 62.3%, which indicates a high pricing power or low cost of goods sold relative to revenue, while the operating margin is -5.0% and the profit margin is -6.4%, signaling that overhead costs and other operating expenses are consuming a substantial portion of the gross profit. On the balance sheet, the company holds $8.87M in cash against $3.50M in debt, resulting in a debt-to-equity ratio of 20.51, which implies a balance sheet that is technically leveraged but heavily weighted toward cash assets. The current ratio is 2.44, indicating that the company possesses 2.44 times more current assets than current liabilities, which points to strong short-term liquidity and the ability to meet its short-term obligations without distress. Furthermore, the return on equity is -15.6% and the return on assets is -6.7%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, reflecting the early-stage or growth-phase nature of the operations.
Valuation Assessment
The valuation metrics for KORU Medical Systems show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed at 51.88, implying that the market is pricing in significant future earnings growth to justify the current stock price. The price-to-book ratio is 11.98, which indicates that the market is valuing the company at a substantial premium over its net book value, reflecting high expectations for future intangible assets or growth potential rather than current tangible asset worth. Alternative valuation measures such as the price-to-sales ratio of 4.97 and an EV/EBITDA of -87.34 are utilized because traditional earnings-based multiples are not applicable given the negative earnings position. The stock has traded between a 52-week low of $1.86 and a 52-week high of $6.61, placing the current market price within a range that demonstrates significant volatility over the past year. With a beta of 0.50, the stock exhibits lower price volatility relative to the broader market, suggesting that its price movements are less sensitive to overall market fluctuations than the average stock.
Growth & Income
The company has demonstrated robust top-line expansion with revenue growth of 23.3% year-over-year, while earnings growth is listed as N/A due to the negative earnings history, indicating that profitability has not yet scaled at the same rate as sales. Because the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where earnings are not distributed to shareholders but are instead retained to fund research, development, and commercialization efforts. This reinvestment approach is typical for companies in the subcutaneous drug delivery market that require continuous innovation to maintain their competitive position against established players. The overall growth and income profile for KORU Medical Systems is characterized by strong revenue acceleration and a complete focus on capital reinvestment, offering investors exposure to a high-growth trajectory rather than current income generation.